An Oral Cholesterol Drug Reduces Cardiac Events in Patients Who Can't Take Statins

Statins are the most prescribed class of drugs in medicine, and for good reason — decades of evidence confirm they reduce heart attacks, strokes, and cardiovascular death in high-risk patients. The problem is that a meaningful subset of patients can't tolerate them. Statin intolerance — usually muscle pain or weakness (myalgia, myopathy) with or without CK elevation — affects somewhere between 5% and 25% of patients, depending on how it's defined. For these patients, the options before CLEAR OUTCOMES were limited: ezetimibe (effective but modest LDL reduction), PCSK9 inhibitors (highly effective but injectable and expensive), and lifestyle measures. Bempedoic acid offered a third oral option — but without cardiovascular outcome data, it was hard to know whether lowering LDL with this drug translated into fewer events.

CLEAR OUTCOMES enrolled 13,970 patients who reported statin intolerance (defined as inability to take two or more statins at any dose due to unacceptable muscle side effects). The population was high-risk: 73% had established cardiovascular disease, 27% were at high risk without prior events. Average LDL at baseline was 139 mg/dL — substantially elevated despite statin avoidance. Participants were randomized to bempedoic acid 180 mg daily or placebo[1]. Bempedoic acid works proximal to the statin target: it inhibits ATP-citrate lyase, an enzyme upstream of HMG-CoA reductase in the cholesterol synthesis pathway. Crucially, it requires activation by an enzyme (ACSVL1) that is present in hepatocytes but not in muscle — which explains why it lowers cholesterol without causing the myopathic side effects that make statins intolerable for some patients.

At a median follow-up of 40.6 months, the 4-MACE primary endpoint (CV death, nonfatal MI, nonfatal stroke, or coronary revascularization) occurred in 11.7% of bempedoic acid patients versus 13.3% of placebo patients — a hazard ratio of 0.87 (95% CI 0.79–0.96; p=0.004)[1]. LDL was reduced by an average of 29.2 mg/dL (21.1%) relative to placebo. The number needed to treat over 3.4 years to prevent one 4-MACE event was approximately 63. Individual component analysis showed significant reductions in nonfatal MI and coronary revascularization; the reduction in CV death and stroke individually did not reach significance.

The trade-off is tolerability. Gout occurred in 3.1% of bempedoic acid patients versus 2.1% on placebo — a statistically significant increase — because bempedoic acid reduces renal uric acid excretion. Hyperuricemia is a known class effect. Cholelithiasis was also numerically more common. These are manageable complications, but clinicians prescribing this drug in patients with a history of gout should weigh the benefit carefully and monitor uric acid levels.

Clinical Context

Where does bempedoic acid fit in the lipid-lowering landscape? It fills a specific niche: the statin-intolerant patient who cannot take injectable PCSK9 inhibitors (cost, access, preference) and whose LDL remains above target on ezetimibe alone. For that patient, bempedoic acid offers meaningful LDL reduction with good oral tolerability and now has cardiovascular outcome data. It does not reach the 50–60% LDL reduction of PCSK9 inhibitors, but it reduces events and is orally available and generic-equivalent formulations will eventually reduce cost.

A fixed-dose combination pill (bempedoic acid + ezetimibe, sold as Nexlizet) combines the two non-statin oral agents and can provide LDL reductions in the 35–45% range — comparable to a moderate-intensity statin. For an internist with a statin-intolerant patient on ezetimibe still not at goal, this combination is now supported by outcome evidence for its components.

Limitations

The trial enrolled only patients reporting statin intolerance — it did not verify this by rechallenge (which is the current standard to confirm true intolerance versus nocebo effect). If some enrollees could have tolerated low-dose statins, the true comparison group may have had a more favorable LDL trajectory than assumed. The 4-MACE primary endpoint included coronary revascularization, a softer outcome than death or MI alone; the reduction in the harder endpoints (CV death, nonfatal stroke) was numerically present but did not reach statistical significance individually.